{"id":"https://openalex.org/W7225329421","doi":"https://doi.org/10.1002/lci2.70059","title":"Farnesoid X Receptor Agonist INT \u2010787 Protects Human Liver Organoids From Alcohol\u2010Induced Injury","display_name":"Farnesoid X Receptor Agonist INT \u2010787 Protects Human Liver Organoids From Alcohol\u2010Induced Injury","publication_year":2026,"publication_date":"2026-11-05","ids":{"openalex":"https://openalex.org/W7225329421","doi":"https://doi.org/10.1002/lci2.70059"},"language":"en","primary_location":{"id":"doi:10.1002/lci2.70059","doi":"https://doi.org/10.1002/lci2.70059","is_oa":true,"landing_page_url":"https://doi.org/10.1002/lci2.70059","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lci2.70059","source":{"id":"https://openalex.org/S4404660569","display_name":"Liver international communications.","issn_l":"2994-1393","issn":["2994-1393"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Liver International Communications","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lci2.70059","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5102879258","display_name":"Francesca De Franco","orcid":"https://orcid.org/0000-0002-5818-9681","observed_orcids":["https://orcid.org/0000-0002-5818-9681"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Francesca De Franco","raw_affiliation_strings":["TES Pharma S.r.l.  Corciano Perugia Italy"],"raw_orcid":"https://orcid.org/0000-0002-5818-9681","affiliations":[{"raw_affiliation_string":"TES Pharma S.r.l.  Corciano Perugia Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000492255","display_name":"Gianmario Ciaccioli","orcid":"https://orcid.org/0009-0004-5581-8210","observed_orcids":["https://orcid.org/0009-0004-5581-8210"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gianmario Ciaccioli","raw_affiliation_strings":["TES Pharma S.r.l.  Corciano Perugia Italy"],"raw_orcid":"https://orcid.org/0009-0004-5581-8210","affiliations":[{"raw_affiliation_string":"TES Pharma S.r.l.  Corciano Perugia Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022604699","display_name":"Marco Cipolloni","orcid":"https://orcid.org/0000-0002-8092-4638","observed_orcids":["https://orcid.org/0000-0002-8092-4638"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marco Cipolloni","raw_affiliation_strings":["TES Pharma S.r.l.  Corciano Perugia Italy"],"raw_orcid":"https://orcid.org/0000-0002-8092-4638","affiliations":[{"raw_affiliation_string":"TES Pharma S.r.l.  Corciano Perugia Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029229898","display_name":"Carolina Colliva","orcid":"https://orcid.org/0000-0001-8360-9142","observed_orcids":["https://orcid.org/0000-0001-8360-9142","https://orcid.org/0000-0002-1675-3141"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carolina Colliva","raw_affiliation_strings":["TES Pharma S.r.l.  Corciano Perugia Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TES Pharma S.r.l.  Corciano Perugia Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010826903","display_name":"Sanjay Kansra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55878746","display_name":"Intercept Pharmaceuticals (United States)","ror":"https://ror.org/01sx6jc36","country_code":"US","type":"company","lineage":["https://openalex.org/I55878746"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay Kansra","raw_affiliation_strings":["Intercept Pharmaceuticals, Inc.  Morristown New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Intercept Pharmaceuticals, Inc.  Morristown New Jersey USA","institution_ids":["https://openalex.org/I55878746"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058458204","display_name":"Luciano Adorini","orcid":"https://orcid.org/0000-0001-8109-339X","observed_orcids":["https://orcid.org/0000-0001-8109-339X"]},"institutions":[{"id":"https://openalex.org/I55878746","display_name":"Intercept Pharmaceuticals (United States)","ror":"https://ror.org/01sx6jc36","country_code":"US","type":"company","lineage":["https://openalex.org/I55878746"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luciano Adorini","raw_affiliation_strings":["Intercept Pharmaceuticals, Inc.  Morristown New Jersey USA"],"raw_orcid":"https://orcid.org/0000-0001-8109-339X","affiliations":[{"raw_affiliation_string":"Intercept Pharmaceuticals, Inc.  Morristown New Jersey USA","institution_ids":["https://openalex.org/I55878746"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111224034","display_name":"Roberto Pellicciari","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roberto Pellicciari","raw_affiliation_strings":["TES Pharma S.r.l.  Corciano Perugia Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TES Pharma S.r.l.  Corciano Perugia Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103257441","display_name":"Mary Erickson","orcid":"https://orcid.org/0000-0002-6514-6073","observed_orcids":["https://orcid.org/0000-0002-6514-6073"]},"institutions":[{"id":"https://openalex.org/I55878746","display_name":"Intercept Pharmaceuticals (United States)","ror":"https://ror.org/01sx6jc36","country_code":"US","type":"company","lineage":["https://openalex.org/I55878746"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mary Erickson","raw_affiliation_strings":["Intercept Pharmaceuticals, Inc.  Morristown New Jersey USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Intercept Pharmaceuticals, Inc.  Morristown New Jersey USA","institution_ids":["https://openalex.org/I55878746"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102804539","display_name":"Daniela Passeri","orcid":"https://orcid.org/0000-0003-0075-4219","observed_orcids":["https://orcid.org/0000-0003-0075-4219","https://orcid.org/0000-0002-0736-753X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniela Passeri","raw_affiliation_strings":["TES Pharma S.r.l.  Corciano Perugia Italy"],"raw_orcid":"https://orcid.org/0000-0003-0075-4219","affiliations":[{"raw_affiliation_string":"TES Pharma S.r.l.  Corciano Perugia Italy","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5103257441"],"corresponding_institution_ids":["https://openalex.org/I55878746"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"7","issue":"4","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11207","display_name":"Alcohol Consumption and Health Effects","score":0.9336000084877014,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11207","display_name":"Alcohol Consumption and Health Effects","score":0.9336000084877014,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10966","display_name":"Liver physiology and pathology","score":0.03830000013113022,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.015200000256299973,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/farnesoid-x-receptor-agonist","display_name":"farnesoid X receptor agonist","score":0.9739999771118164},{"id":"https://openalex.org/keywords/alcoholic-liver-disease","display_name":"alcoholic liver disease","score":0.8980000019073486},{"id":"https://openalex.org/keywords/alcohol-induced-liver-injury","display_name":"alcohol-induced liver injury","score":0.859000027179718},{"id":"https://openalex.org/keywords/human-liver-organoids","display_name":"human liver organoids","score":0.9399999976158142},{"id":"https://openalex.org/keywords/hepatic-steatosis","display_name":"hepatic steatosis","score":0.7950000166893005},{"id":"https://openalex.org/keywords/liver-fibrosis","display_name":"liver fibrosis","score":0.9380000233650208},{"id":"https://openalex.org/keywords/liver-inflammation","display_name":"liver inflammation","score":0.6690000295639038},{"id":"https://openalex.org/keywords/oxidative-stress","display_name":"oxidative stress","score":0.9179999828338623},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.9760000109672546},{"id":"https://openalex.org/keywords/cholestasis","display_name":"cholestasis","score":0.9829999804496765},{"id":"https://openalex.org/keywords/bile-acid-analogues","display_name":"bile acid analogues","score":0.7039999961853027},{"id":"https://openalex.org/keywords/hepatoprotective-effect","display_name":"hepatoprotection","score":0.7289999723434448}],"concepts":[{"id":"https://openalex.org/C2776175330","wikidata":"https://www.wikidata.org/wiki/Q1365091","display_name":"Steatosis","level":2,"score":0.7487999796867371},{"id":"https://openalex.org/C2776637226","wikidata":"https://www.wikidata.org/wiki/Q6658207","display_name":"Liver injury","level":2,"score":0.7149999737739563},{"id":"https://openalex.org/C2779478299","wikidata":"https://www.wikidata.org/wiki/Q2335423","display_name":"Steatohepatitis","level":4,"score":0.618399977684021},{"id":"https://openalex.org/C203862802","wikidata":"https://www.wikidata.org/wiki/Q14905041","display_name":"Farnesoid X receptor","level":5,"score":0.5295000076293945},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49219998717308044},{"id":"https://openalex.org/C2778593092","wikidata":"https://www.wikidata.org/wiki/Q1075923","display_name":"Cholestasis","level":2,"score":0.4875999987125397},{"id":"https://openalex.org/C176891718","wikidata":"https://www.wikidata.org/wiki/Q1997459","display_name":"Hepatic stellate cell","level":2,"score":0.4871000051498413},{"id":"https://openalex.org/C2776151105","wikidata":"https://www.wikidata.org/wiki/Q898814","display_name":"Oxidative stress","level":2,"score":0.482699990272522},{"id":"https://openalex.org/C2779399885","wikidata":"https://www.wikidata.org/wiki/Q413288","display_name":"Bile acid","level":2,"score":0.48260000348091125},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4602999985218048},{"id":"https://openalex.org/C2777575235","wikidata":"https://www.wikidata.org/wiki/Q558404","display_name":"Alcoholic liver disease","level":3,"score":0.45179998874664307},{"id":"https://openalex.org/C2778772119","wikidata":"https://www.wikidata.org/wiki/Q6058862","display_name":"Fatty liver","level":3,"score":0.43369999527931213},{"id":"https://openalex.org/C2780366471","wikidata":"https://www.wikidata.org/wiki/Q1072420","display_name":"Primary biliary cirrhosis","level":2,"score":0.42480000853538513},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4242999851703644},{"id":"https://openalex.org/C2780965833","wikidata":"https://www.wikidata.org/wiki/Q241374","display_name":"Ursodeoxycholic acid","level":2,"score":0.3783000111579895},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.3756999969482422},{"id":"https://openalex.org/C2780559512","wikidata":"https://www.wikidata.org/wiki/Q605709","display_name":"Fibrosis","level":2,"score":0.37470000982284546},{"id":"https://openalex.org/C31695470","wikidata":"https://www.wikidata.org/wiki/Q11293125","display_name":"Organoid","level":2,"score":0.37040001153945923},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.3686999976634979},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.36469998955726624},{"id":"https://openalex.org/C2777214474","wikidata":"https://www.wikidata.org/wiki/Q147778","display_name":"Cirrhosis","level":2,"score":0.36469998955726624},{"id":"https://openalex.org/C2776514860","wikidata":"https://www.wikidata.org/wiki/Q3817359","display_name":"Hepatoprotection","level":4,"score":0.3637000024318695},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.3628000020980835},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.35190001130104065},{"id":"https://openalex.org/C2777075537","wikidata":"https://www.wikidata.org/wiki/Q929737","display_name":"Liver disease","level":2,"score":0.3456999957561493},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.34549999237060547},{"id":"https://openalex.org/C195521686","wikidata":"https://www.wikidata.org/wiki/Q17152676","display_name":"Liver cytology","level":3,"score":0.31189998984336853},{"id":"https://openalex.org/C2992672570","wikidata":"https://www.wikidata.org/wiki/Q827450","display_name":"Liver cell","level":2,"score":0.3001999855041504},{"id":"https://openalex.org/C48349386","wikidata":"https://www.wikidata.org/wiki/Q424361","display_name":"Reactive oxygen species","level":2,"score":0.2971999943256378},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2815000116825104},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.2728999853134155},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.25949999690055847},{"id":"https://openalex.org/C44353895","wikidata":"https://www.wikidata.org/wiki/Q6556772","display_name":"Lipotoxicity","level":4,"score":0.2567000091075897},{"id":"https://openalex.org/C2780829032","wikidata":"https://www.wikidata.org/wiki/Q898539","display_name":"Lipid peroxidation","level":3,"score":0.25619998574256897},{"id":"https://openalex.org/C39321552","wikidata":"https://www.wikidata.org/wiki/Q18052005","display_name":"G protein-coupled bile acid receptor","level":3,"score":0.25440001487731934}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1002/lci2.70059","doi":"https://doi.org/10.1002/lci2.70059","is_oa":true,"landing_page_url":"https://doi.org/10.1002/lci2.70059","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lci2.70059","source":{"id":"https://openalex.org/S4404660569","display_name":"Liver international communications.","issn_l":"2994-1393","issn":["2994-1393"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Liver International Communications","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1002/lci2.70059","doi":"https://doi.org/10.1002/lci2.70059","is_oa":true,"landing_page_url":"https://doi.org/10.1002/lci2.70059","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/lci2.70059","source":{"id":"https://openalex.org/S4404660569","display_name":"Liver international communications.","issn_l":"2994-1393","issn":["2994-1393"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Liver International Communications","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320318040","display_name":"Intercept Pharmaceuticals","ror":"https://ror.org/01sx6jc36"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225329421.pdf","grobid_xml":"https://content.openalex.org/works/W7225329421.grobid-xml"},"referenced_works_count":52,"referenced_works":["https://openalex.org/W1964251823","https://openalex.org/W2001132193","https://openalex.org/W2001381822","https://openalex.org/W2005950118","https://openalex.org/W2010340961","https://openalex.org/W2012257016","https://openalex.org/W2012508659","https://openalex.org/W2012992997","https://openalex.org/W2037981516","https://openalex.org/W2059714773","https://openalex.org/W2092677426","https://openalex.org/W2106128735","https://openalex.org/W2523690932","https://openalex.org/W2767062996","https://openalex.org/W2770310782","https://openalex.org/W2776728489","https://openalex.org/W2797379250","https://openalex.org/W2799832433","https://openalex.org/W2897662939","https://openalex.org/W2912858047","https://openalex.org/W2916029362","https://openalex.org/W2980585186","https://openalex.org/W2993083975","https://openalex.org/W2998313718","https://openalex.org/W2999854159","https://openalex.org/W3086893431","https://openalex.org/W3138927624","https://openalex.org/W3174591877","https://openalex.org/W3190128354","https://openalex.org/W3205378558","https://openalex.org/W4213057636","https://openalex.org/W4285891012","https://openalex.org/W4286685889","https://openalex.org/W4304687342","https://openalex.org/W4307021568","https://openalex.org/W4360993648","https://openalex.org/W4362520806","https://openalex.org/W4368367601","https://openalex.org/W4382988265","https://openalex.org/W4385337271","https://openalex.org/W4385648809","https://openalex.org/W4386701458","https://openalex.org/W4392004980","https://openalex.org/W4392653616","https://openalex.org/W4395478502","https://openalex.org/W4396906941","https://openalex.org/W4399250935","https://openalex.org/W4403928049","https://openalex.org/W4406917635","https://openalex.org/W4409981494","https://openalex.org/W4410546865","https://openalex.org/W4412957527"],"related_works":["https://openalex.org/W4399461448","https://openalex.org/W7162574689","https://openalex.org/W4395478502","https://openalex.org/W2005950118","https://openalex.org/W2897662939","https://openalex.org/W4390635921","https://openalex.org/W4286685889","https://openalex.org/W3024591628","https://openalex.org/W2884994513","https://openalex.org/W431624738"],"abstract_inverted_index":{"ABSTRACT":[0],"Background":[1],"Alcohol\u2010associated":[2],"liver":[3,10,30,45,79,86,91,106],"disease":[4],"(ALD)":[5],"represents":[6,237],"a":[7,238],"spectrum":[8],"of":[9,23,38,63,118,139,186,198,245],"injury":[11,80],"ranging":[12],"from":[13,95],"steatosis":[14,133,232],"to":[15,73,162,228],"alcohol\u2010associated":[16],"hepatitis,":[17],"cirrhosis,":[18],"and":[19,33,43,47,68,105,137,142,144,151,166,171,175,194,204,207,214,233],"hepatocellular":[20],"carcinoma.":[21],"Activation":[22],"the":[24,60,64,116,124,183,242],"farnesoid":[25],"X":[26],"receptor":[27],"(FXR)":[28],"decreases":[29],"steatosis,":[31],"inflammation,":[32,199,211],"fibrosis":[34,145],"in":[35,48,83,115,230],"animal":[36],"models":[37],"liver\u2010related":[39],"diseases,":[40],"including":[41],"cirrhosis":[42],"alcohol\u2010induced":[44,78],"injury,":[46],"patients":[49],"with":[50,101,112],"primary":[51,97,102,176],"biliary":[52],"cholangitis":[53],"or":[54,123],"metabolic":[55],"dysfunction\u2010associated":[56],"steatohepatitis.":[57],"We":[58],"assessed":[59],"therapeutic":[61],"potential":[62],"bile":[65,177],"acid":[66,178],"analogue":[67],"potent":[69],"FXR":[70],"agonist":[71],"INT\u2010787":[72,181,206,224,236],"determine":[74],"its":[75],"effects":[76],"on":[77],"using":[81],"an":[82],"vitro":[84],"human":[85,98],"organoid":[87],"model.":[88],"Methods":[89],"Human":[90],"organoids":[92],"were":[93,110,153],"obtained":[94],"multidonor":[96],"hepatocytes":[99],"cocultured":[100],"Kupffer":[103],"cells":[104],"endothelial":[107],"cells.":[108],"Organoids":[109],"cultured":[111],"alcohol":[113,187,218],"0.5%":[114],"presence":[117],"dimethyl":[119],"sulfoxide":[120],"(control),":[121],"INT\u2010787,":[122],"DNA":[125],"methyltransferase":[126],"inhibitor":[127],"larsucosterol":[128],"(DUR\u2010928).":[129],"On":[130],"day":[131],"4,":[132],"(Nile":[134],"Red":[135],"staining)":[136],"markers":[138,197],"inflammation":[140],"(IL\u20106":[141],"TNF\u2010\u03b1)":[143],"(TGF\u2010\u03b21,":[146],"\u03b1SMA,":[147],"COL1A1,":[148],"COL3A1,":[149],"CTGF":[150],"THBS1)":[152],"assessed,":[154],"as":[155,157],"well":[156],"cell":[158,221],"viability":[159],"(ATP),":[160],"response":[161],"oxidative":[163,201,212],"stress":[164],"(CYP2E1":[165],"COX\u20102),":[167],"apoptotic":[168],"pathways":[169],"(BAX":[170],"BCL2),":[172],"cholestasis":[173],"(MRP2),":[174],"levels.":[179],"Results":[180],"counteracts":[182],"toxic":[184],"effect":[185],"exposure":[188],"by":[189,217],"markedly":[190],"reducing":[191],"lipid":[192],"accumulation":[193],"significantly":[195,226],"decreasing":[196],"fibrosis,":[200],"stress,":[202,213],"apoptosis,":[203],"cholestasis.":[205],"DUR\u2010928":[208,229],"similarly":[209],"inhibit":[210],"apoptosis":[215],"induced":[216],"while":[219],"ameliorating":[220],"viability,":[222],"but":[223],"is":[225],"superior":[227],"inhibiting":[231],"fibrosis.":[234],"Conclusion":[235],"promising":[239],"molecule":[240],"for":[241],"clinical":[243],"treatment":[244],"ALD.":[246]},"counts_by_year":[],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2026-11-06T00:00:00"}